newsfilter
← Earnings
Earnings Releases·

Aptevo Therapeutics — Third Quarter 2026 Earnings Summary

Aptevo Therapeutics reported that its lead candidate mipletamig achieved a 79% remission rate in patients with high-risk TP53-mutated acute myeloid leukemia, a figure nearly double the historical benchmark for similar patients treated with standard therapies. Ten of 47 patients receiving the mipletamig combination therapy advanced to potentially curative stem cell transplantation, while refinements to the drug's priming-dose regimen significantly reduced infusion-related reactions. The company also secured $4.5 million in additional financing to support clinical milestones and advanced its next-generation trispecific candidates toward human testing in solid tumors.

Company
APTEVO THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology